Effect of remifentanil on Tpeak-Tend interval during electroconvulsive therapy

Effect of remifentanil on Tpeak-Tend interval during electroconvulsive therapy - Effect of remifentanil on TpTe

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000051958

Enrollment

Registered

2024-08-21

Start date

2023-08-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia and depression

Interventions

Pretreatment of remifentanil No treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: American Society of Anesthesiologists (ASA) physical status 1 or 2, aged 20 to 65 years, who were scheduled to undergo modified electroconvulsive therapy (mECT) with written informed consent.

Exclusion criteria

Exclusion criteria: We exclude patients with cardiovascular, respiratory, metabolic, or cerebrovascular diseases, and those with preoperative electrocardiogram (ECG) abnormalities, allergy with remifentanil, pregnancy.

Design outcomes

Primary

Measure	Time frame
TpTe, TpTe/QT, TpTe/QTc, TpTe/RR	—

Secondary

Measure	Time frame
Systolic Blood pressure, diastolic blood pressure, RR interval.	—

Countries

Japan

Contacts

Public ContactToshifumi Takasusuki

Dokkyo Medical University Department of Anesthesiology

takasusu@dokkyomed.ac.jp0282-86-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026